A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-04-01

Summary

This is a First-In-Human trial investigating a novel expansion protocol of an ATIMP (CC-38), composed of autologous TIL.

• Phase: PHASE1

Details

• Lead Sponsor: Curacell Holding AB
• Collaborators: Frankfurter Institut fr Klinische Krebsforschung IKF GmbH; Krebsforschung Rhein-Main e.V.; Zellwerk GmbH
• Treatments: Cyclophosphamide; Interleukin-2; Mesna; pembrolizumab